About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.
The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target
Video Jul 03, 2015
It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate and to evaluate the potential of a drug candidate to be a victim or perpetrator. Knowing how a drug candidate is eliminated by the human body is important in understanding the potential for drug-drug interactions.WATCH NOW
In the latest installment of ADME 101, one of our hepatocyte experts answers frequently asked questions about plateable hepatocytes, discusses common reasons why hepatocyte plating fails and demonstrates helpful techniques that will improve the performance of your plated hepatocytes in your in vitro assays.WATCH NOW